Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/43047
Título: Molecular biomarkers in the decision of treatment of cervical carcinoma patients
Autores/as: Valenciano, A.
Henríquez-Hernández, L. A. 
Lloret, M.
Pinar, B.
Lara, P. C.
Palabras clave: Peripheral-Blood Lymphocytes
Normal Tissue-Damage
Major Vault Protein
Igf-1R Expression
Cancer-Patients, et al.
Fecha de publicación: 2013
Editor/a: 1699-048X
Publicación seriada: Clinical and Translational Oncology 
Resumen: Cervical carcinoma is the third most common cancer in women worldwide. The programs developed for early detection have made that most patients are diagnosed in early stages. Treatment for those patients consists of conservative techniques as surgery or radical radiotherapy; however, the decision between those two therapies is still controversial. Even though in many cases this decision varies according to classical associated risk factors (i.e. tumor stage or age), in the clinical practice, a significant number of patients treated by surgery also receive post-surgery radiotherapy, with the consequent over-treatment and toxic effects. Since response to treatments is conditioned by individual factors, the use of new biological markers as novel predictive factors for both tumor and normal tissues could help clinicians to choose the best treatment schedule for each patient individually. Based on the experience of our institution, we have reviewed the new biological markers in cervical carcinoma patients treated by radiotherapy.
URI: http://hdl.handle.net/10553/43047
ISSN: 1699-048X
DOI: 10.1007/s12094-013-1018-0
Fuente: Clinical and Translational Oncology[ISSN 1699-048X],v. 15, p. 587-592
Colección:Artículos
Vista completa

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.